Genetic and clinical factors influence the baseline permeability of the peritoneal membrane  by Gillerot, Gaalle et al.
Kidney International, Vol. 67 (2005), pp. 2477–2487
Genetic and clinical factors influence the baseline permeability
of the peritoneal membrane
GAE¨LLE GILLEROT, ERIC GOFFIN, CATHERINE MICHEL, PIETER EVENEPOEL, WIM VAN BIESEN,
MICHEL TINTILLIER, PETER STENVINKEL, OLOF HEIMBU¨RGER, BENGT LINDHOLM, LOUISE NORDFORS,
ANNIE ROBERT, and OLIVIER DEVUYST
Division of Nephrology, and Division of Epidemiology and Statistics, Universite´ Catholique de Louvain Medical School, Brussels,
Belgium; Division of Nephrology, Hoˆpital Bichat, Paris, France; Division of Nephrology, University Hospital Gasthuisberg,
Leuven, Belgium; Divison of Nephrology, UZ Ghent, Ghent, Belgium; Divison of Nephrology, Clinique Ste Elisabeth, Namur,
Belgium; and Departments of Molecular Medicine and Renal Medicine, Karolinska Institutet, Stockholm, Sweden
Genetic and clinical factors influence the baseline permeability
of the peritoneal membrane.
Background. Patients starting peritoneal dialysis (PD) show
a significant variability in small solute transport across the peri-
toneal membrane (PM). The latter parameter determines dialy-
sis prescription and survival. Clinical factors probably influence
solute transport across the PM, but the putative role of genetic
variants is unknown.
Methods. We have investigated the influence of functional
polymorphisms of VEGF, ENOS, and IL-6, together with clin-
ical and biological factors, on baseline peritoneal equilibration
test (PET) parameters in a homogeneous population of 152 un-
related Caucasian PD patients from Belgium and the North of
France.
Results. The distribution of the 21 alleles (7 polymorphisms)
and linkage disequilibrium parameters were similar in PD pa-
tients and healthy subjects. Univariate and multivariate anal-
yses identified comorbidity, serum albumin, and the −174G/C
polymorphism of IL-6 as independent predictors of small so-
lute transport. The −174G/C polymorphism of IL-6 was asso-
ciated with significantly higher IL-6 mRNA levels in the PM
and higher plasma and dialysate IL-6 concentrations, suggest-
ing a dominant effect of the C allele. Patients harboring the CC
and GC genotypes (N = 92) were characterized by significantly
higher permeability parameters and inflammatory markers than
patients harboring the GG genotype (N = 60). In contrast with
IL-6, VEGF and ENOS polymorphisms had no influence on
baseline peritoneal permeability.
Conclusion. These data (1) show that, together with clinical
parameters, the functionally relevant −174G/C polymorphism
of IL-6 contributes to the interpatient variability in small solute
transport rate at the start of PD; and (2) substantiate the critical
role played by IL-6 in the PM.
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Peritoneal dialysis (PD) is used in approximately
15% of dialysis patients worldwide. The small solute
transport rate, which is clinically assessed by the peri-
toneal equilibration test (PET), determines the dialysis
prescription, and is also a major predictor of patient
and technique survival [1–3]. Twardowski et al first
showed that approximately two thirds of patients have
average transport rate, the remaining one third being
almost equally distributed between high and low trans-
porters [1]. Subsequent series confirmed the existence
of a significant interpatient variability in the baseline so-
lute transport characteristics of the peritoneal membrane
(PM) [2–4]. Clinical factors such as diabetes, cardiovas-
cular comorbidity, and malnutrition likely influence the
peritoneal permeability [2, 5]. Despite recent insights
into the molecular mechanisms regulating PM perme-
ability during PD [6, 7], it remains unknown whether
genetic variants influencing such mechanisms contribute
to the baseline interpatient variability in peritoneal
transport.
The small solute transport rate depends mainly on the
effective surface area (EPSA), which corresponds to the
amount of perfused capillaries within the PM [8]. Clini-
cal and experimental studies have shown that increased
EPSA is associated with increased transport of small so-
lutes and, eventually, ultrafiltration (UF) failure [6, 7].
Accumulating evidence suggests that growth factors such
as vascular endothelial growth factor (VEGF) and cy-
tokines such as interleukin-6 (IL-6), together with the
release of nitric oxide (NO) by endothelial cells, play
a central role in the regulation of vascular density and
permeability within the peritoneum [6–9]. The regulation
of VEGF expression depends on a variety of hormones,
growth factors, and cytokines, including IL-6 [10]. VEGF
is expressed within the human PM, and its abundance
in the dialysate directly correlates with the permeability
of the PM and the loss of UF [11, 12]. The pleiotropic
2477
2478 Gillerot et al: Genetic and clinical factors inﬂuence the peritoneal membrane
IL-6 is an important mediator of inflammation that
increases vascular permeability and stimulates the pro-
duction of acute-phase proteins, such as the C-reactive
protein (CRP) [13]. Several lines of evidence suggest that
the signaling mediated by IL-6 and its soluble receptor
(sIL-6R) plays a key role in both acute and chronic in-
flammation [14, 15]. Various cells within the PM secrete
IL-6 [16], and its plasma and dialysate concentrations
have been associated with high peritoneal solute trans-
port rate [12]. Among its many biological functions, NO
is involved in the regulation of vascular tone and perme-
ability [17], and modulation of angiogenesis [18]. A sig-
nificant endothelial NO synthase (eNOS) activity is de-
tected in the peritoneum [19], and eNOS up-regulation is
clearly involved in permeability changes associated with
peritonitis [20].
Several polymorphisms within the regulatory region
of the genes coding for VEGF, IL-6, and eNOS have re-
cently been identified. These polymorphisms modify the
amount of gene expression in vitro [21–26], which sug-
gests that they could modulate the expression of impor-
tant mediators and influence the permeability of the PM.
The aim of the present study was to evaluate whether ge-
netic factors contribute, in parallel with clinical factors, to
the small solute transport rate at baseline. Our data, ob-
tained in a large series of homogeneous PD patients, sug-
gest that a promoter polymorphism of IL-6 influencing
the expression of IL-6 at the mRNA and protein levels
could influence the baseline solute transport across the
PM.
METHODS
Patients and controls
Patients from a restricted geographic area (150 km ra-
dius) covering central Belgium and the North of France
were consecutively recruited from June 2002 to June 2003
in Saint-Luc Academic Hospital (Brussels, Belgium),
Bichat Academic Hospital (Paris, France), University
Hospital Gasthuisberg (Leuven, Belgium), Clinique Ste-
Elisabeth (Namur, Belgium), University Hospital Ghent
(Ghent, Belgium). All Caucasian patients treated by
PD and having an initial PET performed within one to
six months after PD initiation were included. Patients
with active peritonitis at the time of the PET were ex-
cluded. The patients were unrelated. The Ethics Commit-
tee of each center involved approved the study protocol
(including biopsy analysis when appropriate), and in-
formed consent was obtained from all patients. A pop-
ulation of 103 healthy Caucasian men and women
recruited from University Hospital Gasthuisberg and
Saint-Luc Academic Hospital was used to assess geno-
type distributions and allele frequencies.
Clinical and biological parameters
Detailed physical, clinical, and PD parameters were
obtained for all patients. The intake of drugs, includ-
ing angiotensin-converting enzyme inhibitors (ACEi) or
angiotensin II receptor antagonists (ARA), statins, ni-
trates, corticosteroids, and immunosuppressive treatment
was also recorded. The Wright comorbidity score, which
includes age, diabetes mellitus, active malignancy, coro-
nary heart disease, peripheral vascular disease, and in-
flammatory disease, was determined for each patient
[27]. Cardiovascular comorbidity was defined by at least
one cardiovascular event, including angina pectoris, my-
ocardial infarct, and peripheral arterial disease. Body
surface area (BSA) was calculated as [
√
height (cm) ×
weight (kg)/3600]. Serum albumin at the time of PET
was determined using bromocresol green (serum) or
immunochemistry (dialysate) (Dade Behring, Marburg,
Germany). CRP level at the time of PET was determined
by enzyme-linked immunosorbent assay (ELISA) (Dade
Berhing) in a subset of 56 patients.
Study of small solute transport
The dialysate over plasma concentration ratio for crea-
tinine at 4 hours (D/Pcreat), dialysate over initial dialysate
concentration ratio for glucose at 4 hours (D/D0), and
glucose absorption were determined during the PET per-
formed within one to six months after PD initiation [1, 2].
Peritoneal transport category was based on the D/Pcreat,
which has been shown to be minimally influenced by
dialysate tonicity [28]. The mass transfer area coefficient
for creatinine (MTACcreat), normalized for BSA, was cal-
culated according to the Waniewski model, which cor-
rects for convective transport [29].
DNA extraction and genotyping
Genomic DNA was purified from peripheral blood
leukocytes or frozen dialysate samples using the Purgene
kit® (Gentra, Minneapolis, MN, USA). All polymerase
chain reaction (PCR) amplifications were carried out in
20 lL, using 100 ng of genomic DNA. Genotyping for the
intron 4 VNTR and exon 7 Glu298Asp polymorphisms of
ENOS were performed using primers, PCR conditions,
and digestion by MboI and BanII (Life Technologies,
Carlsbad, CA, USA), as described previously [21, 22].
Genotyping for the VEGF polymorphism −2578C/A was
performed using primers and PCR conditions described
earlier [24], whereas the −1154G/A and +405G/C VEGF
polymorphisms were analyzed by PCR followed by MnlI
and BsmFI digestion, respectively [23, 24]. Genotyping
for the −174G/C and −597G/A polymorphism of IL-6
were performed by PCR followed by NlaIII and FokI
digestion, respectively [25, 26]. The −174G/C genotype
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was subsequently verified by pyrosequencing analysis, as
described previously [30].
Determination of IL-6, VEGF, and NO metabolites in
plasma and dialysate
The plasma and dialysate IL-6 concentrations at time
of the PET were determined using ELISA (Quantikine®,
R&D Systems, Inc., Minneapolis, MN, USA) in all 56
patients for which samples were available. These 56 pa-
tients were similar in terms of peritoneal permeability
(D/Pcreat, MTACcreat), age, gender, plasma albumin, and
Wright score than the rest (N = 96) of the cohort. The
human IL-6 assay has been validated in the plasma, with
an intra-assay (N = 20) and interassay (N = 36) pre-
cision averaging 7% and 8%, respectively. The average
recovery of IL-6 spiked to levels throughout the range
of the assay in the EDTA plasma was 97% (N = 8). The
immunoassay is calibrated against a highly purified Es-
cherichia coli-expressed recombinant human IL-6 (R&D
Systems). The mean minimum detectable dose of IL-6
was 0.039 pg/mL. The linearity of the assay was systemat-
ically verified >99% using standards that have appropri-
ately been diluted to produce samples within the dynamic
range of the assay. There was no cross-reactivity for other
human cytokines, including IFN-c and IL-4. The con-
centrations of VEGF (Quantikine®) and nitrate/nitrite
(NOx; Cayman Chemical, Ann Arbor, MI, USA) were
determined in 32 randomly selected dialysate samples.
All analyses were performed in duplicate.
Quantitative real-time RT-PCR analysis of IL-6 mRNA
expression in human peritoneum
The transcriptional effect of the −174G/C polymor-
phism of IL-6 was investigated by quantitative real-time
reverse transcription (RT)-PCR on eight human peri-
toneum biopsies (parietal peritoneum) from patients in-
cluded in the study. These PD patients were similar
to the rest of the cohort in terms of peritoneal trans-
port and clinical parameters. Four patients harbored the
−174GG, and four the −174CC genotype. Two biop-
sies were obtained at time of catheter insertion, and
two at renal transplantation in each group. The sam-
ples were homogenized in Trizol (Invitrogen, Merelbeke,
Belgium). RNA samples were treated with DNAse I
(MBI Fermentas GMBH, St. Leon-Rot, Germany), and
reverse transcribed into cDNA by using Superscript II
(Invitrogen). The primers for GAPDH and IL-6 were
as follows: 5′ AGAGGCACTGGCAGAAAACA 3′ an-
tisense 5′ CACAGCTCTGGCTTGTTCCT 3′ (IL-6); 5′
GGGGCTCTCCAGAACATCAT 3′ antisense 5′ TCTA-
GACGGCAGGTCAGGT 3′ (GAPDH). The length of
amplicons were 184 bp (IL-6) and 149 bp (GAPDH). The
PCR products were size fractionated on 1.5% agarose,
stained with ethidium bromide, purified by Qiaquick gel
extraction kit (Qiagen, Leusden, The Netherlands), and
sequenced by Genome Express (Grenoble, France).
Real-time RT-PCR (iCycler, Bio-Rad, Hercules, CA,
USA) analyses were performed in duplicate with 200
nmol/L of both sense and antisense primers in a final
volume of 25 lL using iSupermix (Bio-Rad). PCR condi-
tions were settled as incubation at 94◦C for three minutes,
followed by 40 cycles of 30 seconds at 95◦C, 30 seconds
at 61◦C, and one minute at 72◦C. The melting temper-
ature of PCR product was checked at the end of each
PCR by recording SYBR Green fluorescence increase
upon slowly renaturing DNA. A control PCR without
template DNA was performed in each experiment. To
determine the absolute copy number of the target tran-
script, a cloned plasmid DNA for IL-6 and GAPDH was
used to generate a standard curve. The PCR products
were cloned into a pTZ57R vector (MBI Fermentas) and
transformed in JM 107 competent cells (MBI Fermentas).
A standard curve was generated from serial 10-fold dilu-
tions of the purified plasmid containing the appropriate
cDNA. Regression analyses of the Ct (threshold cycle)
values of the standard dilution series were used to deter-
mine the amplification efficiency. The absolute amount of
molecules in the experimental samples was determined
by extrapolating the Ct values from the standard curves.
The standardized ratio (IL-6 mRNA/GAPDH mRNA)
will be referred to as the relative amount of IL-6 mRNA
[31].
Statistical analysis
Continuous data are given as mean ± SD (Tables 1 to
5) and mean ± SEM (Figures 1 to 5). Categorical data
are given as absolute counts and percentage. The chi-
square test (v 2) was used to compare genotype and al-
lele frequencies in PD patients and controls. Comparison
between transport groups was assessed by two-tailed un-
paired t test for continuous data, and Fisher exact test for
categorical variables. Linear associations were assessed
by Pearson correlation. The plasma and dialysate concen-
trations of IL-6 according to the genotype were compared
using analysis of variance (ANOVA). The two-tailed un-
paired t test, with Welch’s correction when appropriate,
was used to compare the effect of IL-6 genotype on small
solute transport. No adjustments have been made for
multiple comparisons in the univariate analysis [32].
Multivariate regressions were conducted in order to
verify whether small solute transport (assessed by the
D/Pcreat) still correlated with genetic polymorphisms af-
ter adjustment to potential confounders [32]. In the stud-
ied population, M represents the more frequent (major)
allele, and m represents the less frequent (minor) allele.
Polymorphisms were coded into two classes to test dom-
inant (0 = M/M, 1 = M/m or m/m) and recessive models
(0 = M/M or M/m, 1 = m/m), or in three classes to test the
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Table 1. Comparison of peritoneal equilibration test (PET) and clinical parameters between the different transport groups in 152 PD patients
Low (L) Low average (LA) L/LA High average (HA) High (H) HA/H
N = 22 N = 42 N = 64 N = 56 N = 32 N = 88 P value
D/Pcreat 0.54 ± 0.05 0.66 ± 0.02 0.62 ± 0.07 0.75 ± 0.03 0.86 ± 0.05 0.79 ± 0.06
MTACcreat 7.5 ± 1.5 9.6 ± 1.5 8.9 ± 1.6 12.7 ± 2.2 17 ± 4 14.3 ± 3.7
mL/min/1.73m2
Glu Abs% 56 ± 6 66 ± 5 63 ± 7 72 ± 6 80 ± 5 75 ± 3
Time on PD before PET weeks 13 ± 8 10 ± 8 11 ± 8 11 ± 8 12 ± 9 11 ± 8 0.7
Age years 52 ± 18 52 ± 18 52 ± 18 59 ± 16 62 ± 12 60 ± 15 0.002
Gender (F/M) 15/7 17/25 32/32 20/36 13/19 33/55 0.13
BSA m2 1.68 ± 0.25 1.76 ± 0.25 1.73 ± 0.24 1.77 ± 0.14 1.73 ± 0.18 1.76 ± 0.16 0.35
Diabetes 3 (14%) 2 (5%) 5 (8%) 10 (18%) 11 (34%) 21 (24%) 0.009
(type 1 and 2) N (%)
Peritonitis before PET N (%) 2 (9%) 1 (2%) 3 (5%) 5 (9%) 6 (19%) 11 (12%) 0.15
Comorbid gradea N (%) 0.0005
Low 14 (64%) 24 (57%) 38 (59%) 23 (41%) 8 (25%) 31 (35%)
Medium 6 (27%) 14 (33%) 20 (31%) 19 (34%) 12 (37%) 31 (35%)
High 2 (9%) 4 (10%) 6 (10%) 14 (25%) 12 (37%) 26 (30%)
Albumin g/dL 3.8 ± 0.3 3.8 ± 0.4 3.8 ± 0.5 3.4 ± 0.4 3.4 ± 0.4 3.4 ± 0.4 <0.0001
Ultrasensitive 0.6 ± 0.8 1.1 ± 1.8 0.2
CRP mg/dL (N = 23) (N = 36)
ACEi or ARA 10 (45%) 14 (33%) 24 (37%) 34 (61%) 19 (59%) 53 (60%) 0.008
N (%)
D/Pcreat, dialysate over plasma ratio for creatinine at 4 hours; MTACcreat, mass transfer area coefficient for creatinine; Glu Abs, glucose absorption; PET, peritoneal
equilibration test; PD, peritoneal dialysis; BSA, body surface area; ACEi, angiotensin-converting enzyme inhibitor; ARA, angiotensin II receptor antagonist. Values are
given as mean ± SD. Comparison between L/LA and HA/H groups was assessed by unpaired t test for continuous data and Fisher exact test for categorical variables.
a Wright index [27].
codominant model (0 = M/M, 1 = M/m, 2 = m/m). First,
a baseline linear regression was established using age and
Wright score as continuous variables and men, diabetes,
and albumin as dummy variables. Next, four polymor-
phisms not in linkage disequilibrium (ENOS Glu298Asp,
VEGF −1154G/A, VEGF +405G/C, and IL-6 −174G/C)
were introduced as a sixth variable in linear regression,
and the change in log-likelihood v 2 statistic was com-
puted to assess the independent correlation value of each
polymorphism with the D/Pcreat. The polymorphism with
the highest v 2 was kept as the sixth variable in linear re-
gression, and the three remaining polymorphisms were
introduced in turn as a seventh variable to check for an
additional correlation value with the D/Pcreat. Statistical
analysis was performed using Instat 3 software (Graph-
Pad Software, Inc.). Significance is defined as P < 0.05.
RESULTS
Clinical and peritoneal permeability characteristics
A total of 206 PD patients were recruited in Belgium
and France, 54 of which were excluded because the ini-
tial PET was performed during active peritonitis (N =
5) or outside the one- to six-month period (N = 36), or
clinical data were lacking (N = 13). Thus, the study popu-
lation consisted of 152 PD patients with a mean age of 57
± 1.4 years, and a male to female ratio of 87/65. Causes
of renal failure included: chronic glomerulonephritis (N
= 46), hypertensive nephropathy (N = 30), interstitial
nephritis (N = 22), diabetic nephropathy (N = 16), poly-
cystic kidney disease (N = 12), Alport’s syndrome (N =
5), and other/unknown (N = 21).
The mean duration of PD before the initial PET was
11 ± 1 weeks (range 4–24 weeks). Thirteen (9%) patients
had one episode of treated peritonitis at least one month
before the PET. The mean characteristics of the initial
PET were the following: D/Pcreat, 0.72 ± 0.12, MTACcreat,
12.3 ± 3.6 mL/min/1.73m2, glucose absorption, 70 ± 9%.
Although only five patients (4%) fell into the previously
described low category [1], the D/Pcreat among the study
population showed a Gaussian distribution (23 patients
(15%) low (L), 41 patients (27%) low-average (LA),
56 patients (37%) high-average (HA), and 32 patients
(21%) high (H) when using the criteria defined by Rodby
et al [4].
Distribution of VEGF, ENOS, and IL-6 polymorphisms
The distribution of the 21 alleles (7 polymorphisms in
3 genes) was similar in the different centers and, for the
whole study population, did not differ from the healthy
Caucasian population. For each polymorphism, the ob-
served genotype frequencies did not deviate from the
Hardy-Weinberg equilibrium (data not shown). Similar
linkage disequilibrium parameters were observed in our
study population and previously studied Caucasian pop-
ulations regarding the association between the a allele of
intron 4 VNTR and the Glu allele of the Glu298Asp poly-
morphism of ENOS [33], the −2578G/A and −1154G/A
VEGF polymorphisms [24], and the IL-6 −174G/C and
−597G/A polymorphisms [26].
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Influence of clinical parameters on the initial PET
characteristics
The univariate analysis of clinical parameters accord-
ing to PET characteristics in the 152 PD patients is shown
in Table 1. The patients were defined according to the
PET, and subsequently included into L/LA (N = 64) and
HA/H (N = 88) groups for statistical analyses. The mean
D/Pcreat was 0.62 ± 0.07 versus 0.79 ± 0.06, the mean
MTACcreat 8.9 ± 1.6 versus 14.3 ± 3.7, and the mean glu-
cose absorption 63 ± 7% versus 75 ± 3% in the L/LA
versus HA/H groups, respectively. The groups were simi-
lar for duration of PD before the PET, gender ratio, BSA,
type of nephropathy, and peritonitis episodes. The HA/H
group showed a significantly higher age (60 ± 15 years
vs. 52 ± 18 years in L/LA), a higher proportion of dia-
betic patients (24% vs. 8% in L/LA), a higher prevalence
of high-grade comorbidity (30% vs. 10% in L/LA), and
a higher proportion of patients with cardiovascular dis-
ease and treatment with ACEi or ARA (60% vs. 37% in
L/LA). Ultrasensitive CRP levels tended to be higher in
the HA/H group. The proportions of prior renal trans-
planted patients and patients under steroid and/or im-
munosuppressive treatment were significantly higher in
the L/LA group.
The relationship between the comorbidity grade and
serum albumin and permeability parameters is illustrated
in Figure 1. The MTACcreat was significantly higher in
PD patients with a high or medium grade of comor-
bidity (high: 13.4 ± 6.3 mL/min/1.73m2; medium: 12.9
± 5.3 mL/min/1.73m2; low: 10.7 ± 3.2 mL/min/1.73m2)
(Fig. 1A). Serum albumin was significantly lower in the
HA/H versus the L/LA group (3.4 ± 0.4 vs. 3.8 ± 0.5 g/dL,
P < 0.0001), and a negative correlation between serum al-
bumin and the MTACcreat (Pearson r = −0.22, P = 0.005)
was observed (Fig. 1B).
Distribution of genotypes according to the initial PET
characteristics
The distribution of the ENOS, VEGF, and IL-6 geno-
types among PD patients according to PET character-
istics is shown in Table 2. The distribution of ENOS
and VEGF polymorphisms was similar in each trans-
port group. However, the distribution of the −174G/C
and −597G/A polymorphisms of IL-6, which were
in complete linkage disequilibrium, was significantly
different among the two transport groups. In com-
parison with the HA/H group, where the genotype
distribution was similar to that observed in the gen-
eral population, the L/LA group was characterized by a
lower prevalence of the CC/GC alleles (69% vs. 49%,
respectively) and a higher prevalence of the GG al-
lele (31% vs. 51%, respectively) of the IL-6 −174G/C
polymorphism.
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Fig. 1. Relationship between the comorbidity grade (A) and serum
albumin concentration (B) and the mass transfer area coefficient for
creatinine (MTACcreat) in the 152 PD patients. (A) The comorbidity
grade exerts a significant influence the MTACcreat (high grade: 13.4
± 0.6 mL/min/1.73m2; medium grade: 12.9 ± 0.6 mL/min/1.73m2; low
grade: 10.7 ± 0.4 mL/min/1.73m2, ANOVA, P = 0.003). (B) Correlation
between serum albumin level and MTACcreat.
Influence of clinical and genetic factors on the initial PET:
multivariate analysis
As shown in Table 3, the baseline linear regression
identified two factors as predictors of the small solute
transport assessed by the D/Pcreat: the Wright score
(P = 0.02) and serum albumin (P = 0.01). VEGF
−1154G/A and +405G/C, and IL-6 −174G/C polymor-
phisms still correlated independently with the D/Pcreat
in the dominant model after adjustment to potential
confounders. However, when VEGF polymorphisms
were introduced after IL-6 polymorphism in regres-
sion, only IL-6 −174G/C polymorphism remained sig-
nificant (VEGF −1154 G/A: v 2 = 0.91, P = 0.34; VEGF
+405G/C: v 2 = 1.44, P = 0.23).
A conventional, data-driven analysis confirmed that
the IL-6 polymorphism is a significant predictor of peri-
toneal transport at baseline. When submitting conjointly
the clinical variables (gender, r = 0.17, P = 0.04; age, r
= 0.05, P = 0.59; diabetes, r = 0.06, P = 0.45; serum
albumin, r = −0.25, P = 0.002; Wright index, r = 0.32,
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Table 2. Distribution of the ENOS, VEGF, and IL-6 genotypes according to the peritoneal transport characteristics obtained during the initial
PET in 152 PD patients
Low (L) Low average (LA) High average (HA) High (H) L/LA vs. HA/H
N = 22 N = 42 N = 56 N = 32 P value
ENOS Glu298Asp GG 6 (27%) 19 (45%) 17 (30%) 12 (37%) 0.63
GT 13 (60%) 18 (43%) 33 (59%) 16 (50%)
TT 3 (13%) 5 (12%) 6 (11%) 4 (13%)
Intron 4 VNTR bb 14 (64%) 26 (62%) 36 (64%) 20 (63%) 0.79
ba 8 (36%) 13 (31%) 19 (34%) 10 (31%)
aa 0 3 (7%) 1 (2%) 2 (6%)
VEGF −2578C/A CC 8 (37%) 14 (35%) 15 (26%) 6 (18%) 0.93
CA 9 (40%) 17 (41%) 30 (54%) 12 (38%)
AA 5 (23%) 14 (34%) 11 (20%) 14 (44%)
−1154G/A GG 11 (50%) 22 (52%) 20 (36%) 8 (25%) 0.14
GA 10 (45%) 13 (31%) 34 (60%) 19 (60%)
AA 1 (5%) 7 (17%) 2 (4%) 5 (15%)
+405G/C GG 7 (31%) 14 (33%) 18 (32%) 17 (52%) 0.34
GC 13 (60%) 18 (43%) 30 (54%) 10 (32%)
CC 2 (9%) 14 (34%) 8 (14%) 5 (16%)
IL-6 −174G/C GG 15 (68%) 17 (41%) 19 (34%) 8 (25%) 0.019
GC 6 (28%) 20 (48%) 29 (52%) 18 (56%)
CC 1 (4%) 5 (11%) 8 (14%) 6 (19%)
−597G/A GG 15 (68%) 17 (41%) 19 (34%) 8 (25%) 0.019
GA 6 (28%) 20 (48%) 29 (52%) 18 (56%)
AA 1 (4%) 5 (11%) 8 (14%) 6 (19%)
Genotype frequencies were compared between L/LA and HA/H groups using v 2 test.
Table 3. Multivariate regression model for the peritoneal
permeability (D/Pcreat)
Improvement
log-likelihood
B ± SE P value v 2 P value
Baseline variables
Male gender 0.03 ± 0.02 0.07
Age 0.0001 ± 0.001 0.86
Diabetes 0.008 ± 0.023 0.73
Wright score 0.031 ± 0.014 0.02
Albumin −0.04 ± 0.02 0.01
Polymorphisms (dominant model)
ENOS Glu298Asp 0.01 0.94
VEGF − 1154G/A 4.26 0.04
VEGF + 405G/C 4.10 0.05
IL-6 − 174G/C 4.69 0.03
P < 0.001) and the IL-6 −174G/C polymorphism (r =
0.19, P = 0.02) to a stepwise selection procedure, the in-
dependent variables were (step 1) the Wright index, R2
= 0.10, F-change P < 0.001; (step 2) albumin, R2 = 0.16,
F-change P = 0.002; and (step 3) IL-6 polymorphism,
R2 = 0.18, F-change P = 0.03.
After stratification by country/major center, the asso-
ciation of the GG genotype of the −174G/C polymor-
phism of IL-6 with a lower peritoneal permeability was
confirmed in the population originating from either UCL,
Brussels [MTACcreat: GG (N = 39) 10.7 ± 0.5 vs. CC+GC
(N = 60) 12.2 ± 0.5, P = 0.015], or Bichat Hospital, Paris
[MTACcreat: GG (N = 17) 12 ± 1 vs. CC+GC (N = 22)
15 ± 0.8, P = 0.014].
Influence of IL-6 genotype on biochemical, clinical, and
transport parameters
To document the putative biological effect of the
−174G/C polymorphism of IL-6, we performed detailed
expression studies of IL-6 mRNA in eight peritoneal
biopsies from patients included in the study. Quanti-
tative real-time RT-PCR showed that the expression
of IL-6 mRNA was significantly higher in the parietal
peritoneum of patients harboring the −174CC genotype
(Fig. 2A to C).
Plasma and dialysate concentrations of IL-6 at time
of the initial PET were determined to substantiate the
biological link between the −174G/C polymorphism of
IL-6 and peritoneal permeability (Fig. 3). The plasma
and dialysate concentrations of IL-6 were significantly
higher in patients harboring the CC and GC genotypes
compared with the GG patients [plasma IL-6 (geomet-
ric means 95% CI): 6.75 (4.07–10.96) and 5.5 (3.72–7.94)
vs. 2.58 (1.82–3.55) respectively, ANOVA, P = 0.002]
[dialysate IL-6 (geometric means 95% CI): 86.81 (40.74–
181.97) and 97.95 (51.29–181.97) vs. 29.83 (20.89–40.74)
respectively, P = 0.003]. Furthermore, the 34 patients har-
boring the GC/CC genotype had a significantly higher
CRP level than the 22 GG patients (1.55 ± 0.44 vs. 0.60
± 0.21, P = 0.04). In contrast, the dialysate concentra-
tions of VEGF and NOx metabolites were similar in all
patients. These data suggest that the C allele of the IL-6
−174G/C polymorphism acts in a dominant way to in-
crease the production of IL-6 in plasma and dialysate,
which could be reflected by a selective increase in the
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Fig. 2. Effect of the −174G/C polymorphism of IL-6 on the expression of IL-6 mRNA in the peritoneum: quantitative real-time RT-PCR analysis.
(A) Standard curves of amplification for IL-6 and GAPDH in peritoneum samples: the slopes (mean of 3 independent experiments) were obtained
by linear regression, and they were similar for GAPDH (−3.46 ± 0.06) and IL-6 (−3.41 ± 0.06). The threshold cycle (Ct) is the number of cycles
at which the fluorescence signal reached a fixed threshold above baseline. (B) Representative real-time RT-PCR tracings of IL-6 versus GAPDH
in the peritoneum of PD patients harboring either the −174CC or the −174GG variant of IL-6. The duplicate curves are shown. The threshold
levels in this tracing were 26.3 (GAPDH), 33.8 (−174CC IL-6), and 35.8 (−174GG IL-6). (C) Quantification of the mRNA expression of IL-6 in
the peritoneum of four PD patients harboring either the −174CC (black bar) or the −174GG (gray bar) genotype (copies of IL-6 normalized to
copies of GAPDH: 4.07 ± 1.9 × 10−3 vs. 0.6 ± 0.3 × 10−3, P = 0.03).
production of CRP. Of note, the albumin concentration
in the dialysate of the 34 patients with the GC/CC geno-
type was significantly higher than in the 22 patients har-
boring the GG genotype (1328 ± 746 mg/L vs. 848 ± 324
mg/L, P = 0.006), further evidencing higher peritoneal
permeability in the former.
These biochemical findings were reflected by the influ-
ence of the IL-6 −174G/C genotype on solute transport
parameters (Fig. 4). The MTACcreat was indeed signifi-
cantly lower among patients harboring the GG genotype
than CC or GC patients (10.7 ± 0.4 vs. 12.9 ± 0.8 or
12.8 ± 0.5, ANOVA, P = 0.006), confirming the domi-
nant effect of the C allele. Analysis of the PD transport
and clinical parameters according to the dominant model
(Table 4) confirmed that MTACcreat, D/Pcreat, and glucose
absorption were all significantly lower in patients harbor-
ing the GG genotype. The GG patients were also char-
acterized by significantly higher serum albumin levels,
whereas other clinical parameters, including age, gender,
BSA, comorbidity grade, number of peritonitis episodes,
and duration of PD were similar in both groups. It must
be noted that the results were similar when the 13 pa-
tients with peritonitis more than one month before the
PET were excluded from the analysis. For the remaining
139 patients, the values for the MTAC creatinine are the
following: CC + GC (N = 85): 12.7 ± 4.2 vs. GG (N =
54): 10.6 ± 3.2; P = 0.0023.
DISCUSSION
We have investigated the effects of polymorphisms of
ENOS, VEGF, and IL-6 together with clinical parame-
ters on the small solute transport rate during the initial
PET in a large series of PD patients. No effect was found
for ENOS and VEGF polymorphisms. In contrast, the
−174G/C polymorphism of IL-6 was identified as an in-
dependent predictor of peritoneal permeability, together
with comorbidity and serum albumin level. Most impor-
tantly, this promoter polymorphism of IL-6 influenced
the expression of IL-6 both at the mRNA and protein lev-
els, with a dominant effect of the C allele on the plasma
and dialysate concentrations of IL-6, mirroring the effect
on solute transport.
Our study provides the first detailed investigation of
the potential role of genetic factors in regulating the base-
line solute transport across the PM. Based on the emerg-
ing framework of molecular mechanisms that regulate
the microvascular density and permeability during PD
[6–9], we selected genes coding for the key mediators IL-
6, VEGF, and eNOS. Considering the inclusion criteria
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181.97) and 97.95 (51.29–181.97) vs. 29.83 (20.89–40.74) respectively,
P = 0.003].
and the necessity to investigate patients similar in terms
of PD modalities and care in general, we could analyze a
large series of unrelated PD patients with a similar ethnic
background, and originating from a relatively restricted
geographic area. For each of the three genes considered,
we selected frequent polymorphisms that have previously
been shown to regulate the transcription in vitro [21–
26]. Population stratification and spurious allelic associa-
tions should be a concern in association studies in general.
However, the inclusion criteria and general characteris-
tics of our cohort are clearly distinct from the conditions
associated with stratification bias [34]. First, our popula-
tion is homogenous in terms of race, ethnic background,
and geographic area. Second, the patients were systemat-
ically included in the study, and the origin of renal failure
in this group is similar to our dialysis population at large.
Third, the population showed a Gaussian distribution of
the permeability parameter, and the influence of classic
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Fig. 4. Influence of the −174G/C polymorphism of IL-6 on the mass
transfer area coefficient for creatinine (MTACcreat) in the 152 PD pa-
tients. The MTACcreat was significantly lower among patients harboring
the CC and GC genotypes than in patients with the GG genotype (12.9
± 0.8 and 12.8 ± 0.5 vs. 10.7 ± 0.4 mL/min/1.73m2, ANOVA, P = 0.006).
Table 4. Influence of the −174G/C polymorphism of IL-6 on
peritoneal transport and clinical and biochemical parameters in the
152 PD patients
IL-6-174G/C
polymorphism
GG GC+CC
(N = 60) (N = 92) P value
MTACcreat mL/min/1.73m2 10.70 ± 3.38 12.85 ± 4.21 0.002
D/Pcreat 0.69 ± 0.11 0.74 ± 0.10 0.004
Glu Abs% 67 ± 9 72 ± 9 0.002
Age years 58 ± 17 55 ± 16 0.3
Gender (F/M) 28/32 37/55 0.5
BSA m2 1.78 ± 0.2 1.72 ± 0.2 0.1
Peritonitis episodes before
PET N (%)
5 (8%) 6 (6%) 0.4
Comorbidity gradea N (%) 0.2
Low 30 (50%) 39 (42%)
Medium 21 (35%) 30 (33%)
High 9 (15%) 23 (25%)
Albumin g/dL 3.7 ± 0.5 3.5 ± 0.5 0.02
Time on PD before PET
weeks
12 (4–24) 11 (4–24) 0.5
MTACcreat, mass transfer area coefficient for creatinine; D/Pcreat, dialysate over
plasma ratio for creatinine at 4 hours; Glu Abs, glucose absorption; BSA, body
surface area. Values are given in mean ± SD. The two groups were compared
using unpaired t test.
aWright index [27].
clinical factors was verified by univariate analysis. Fourth,
two types of genomic controls have been performed. The
distributions of the 21 alleles (7 polymorphisms on differ-
ent chromosomes) were similar in our cohort of patients
and healthy controls from the same area. Similar link-
age disequilibrium parameters were also found for the
polymorphisms of ENOS, IL-6, and VEGF in our cohort
and the healthy population. We feel that these clinical and
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genetic data strongly argue against population admixture
in our study population.
Among a wide range of biological activities, IL-6 pro-
motes the release of CRP and simultaneously suppresses
albumin production by hepatocytes, and it influences vas-
cular permeability in vitro [13]. Moreover, the IL-6/sIL-
6R signaling emerges as a complex regulator of cytokines
and growth factors involved in acute and chronic inflam-
mation [14, 15]. Increased levels of plasma IL-6 and CRP
predict cardiovascular morbidity and overall mortality
[35]. Relevant to this study, inflammation has been asso-
ciated with the peritoneal transport status in prevalent
PD patients [36], and plasma and dialysate IL-6 concen-
trations are increased among H/HA PD patients [12].
There is, thus, a rationale to investigate whether peri-
toneal permeability could be influenced by functional
polymorphisms of IL-6, including the −174G/C polymor-
phism known to influence both the endothelial function
[37] and the inflammatory response [38].
Our univariate and multivariate analyses show that the
−174G/C polymorphism of IL-6 influences the baseline
permeability for small solutes in this series of PD pa-
tients. The conventional analysis confirmed that, together
with the Wright index and serum albumin, the IL-6 poly-
morphism is a significant predictor of peritoneal trans-
port at baseline. In this model, the independent variables
account for ∼20% of the variability in solute transport,
whereas the IL-6 polymorphism alone accounts for only
2% of the variability. It is interesting to note that similar
conclusions have recently been evidenced in a large co-
hort of 574 new PD patients, in which the clinical vari-
ables accounted for ∼20% of the variability in solute
transport, whereas individual factors had little influence
(for instance, age accounted only for 2% of the variabil-
ity) [39]. Subsequent analysis in our population showed a
strong effect of the C allele of this polymorphism on the
MTACcreat (Fig. 4), and the association of the −174G/C
polymorphism with small solute transport was also found
in subgroups stratified by country (Belgium vs. France).
The molecular basis of the effect of this −174G/C poly-
morphism has been previously attributed to the associa-
tion of the C allele with higher plasma levels of IL-6 and
CRP [40, 41], although these results have been challenged
by others [25].
Based on quantitative real-time RT-PCR analysis, we
have shown that the −174G/C promoter polymorphism
exerts an influence on the transcription of IL-6 in the PM
(Fig. 2). Patients harboring the GC and CC genotypes
have higher IL-6 levels in plasma and dialysate (Fig. 3)
and higher transport parameters (Fig. 4) than patients
with the GG genotype, suggesting that the C allele exerts
a dominant effect to increase local IL-6 production and
influence solute transport. It is tempting to speculate that
inflammation may be the link between the genetic variant
and peritoneal transport. This hypothesis is supported by
the fact that increased IL-6 production in our PD patients
is associated with a higher CRP level, as well as by the
demonstration of low serum albumin as an independent
predictor of PM transport (see below). Beyond the po-
tential genetic influence, the production of IL-6 may also
be regulated by other, clinical factors. Elevated levels of
IL-6 are associated with aging, type 2 diabetes mellitus,
cardiovascular morbidity, and chronic stress [13, 42]. Yet
the H/HA patients in our cohort were older and charac-
terized by a higher comorbidity (as assessed by the Wright
score that includes age and diabetes), a higher percentage
of diabetics, and a higher proportion of treatment with
ACEI/ARA (Table 1). After multivariate analysis, the
Wright score, as well as serum albumin and the IL-6 poly-
morphism, remained independent predictors of small so-
lute transport across the membrane. It is, thus, possible
that high comorbidity, including older age and diabetes, is
associated with increased inflammatory response and IL-
6 production, which, in turn, could modify the peritoneal
microcirculation and small solute transport.
In addition to pleiotropic cytokines such as IL-6,
growth factors and vasoactive mediators have a potential
influence on the structure and permeability of the peri-
toneum [6, 7]. In contrast with IL-6, VEGF and ENOS
polymorphisms were not identified as independent pre-
dictors of baseline solute transport (there was a minor
effect of VEGF polymorphisms that was not confirmed
in the multivariate analysis). This negative result may re-
flect the lack of biological effect of these variants, since
no significant differences in VEGF and NOx levels were
detected. The effect of profibrotic growth factors such as
TGF-b or FGF2 was not investigated here. It is tempting
to hypothesize that genetic variants in growth factors may
be particularly important for the longitudinal changes in
the membrane exposed to the dialysate [6–9]. Investiga-
tion of this hypothesis will have to take into account the
potential influence of many factors, including drugs (such
as ACEi or ARA) that may interfere with the release of
such factors.
Baseline peritoneal transport is associated with comor-
bidity and serum albumin in this series of PD patients.
The Wright score of comorbidity includes clinical fac-
tors (age, diabetes mellitus, cardiovascular disease) as-
sociated with peritoneal transport in univariate analysis.
Although potentially interesting, interpretation of the ef-
fect of prior renal transplantation, and immunosuppres-
sive drugs, ACEi, or ARA, is hampered by low numbers
or correlation with cardiovascular comorbidity. The as-
sociation between low albumin and increased transport
rate has been reported by others [2, 12, 39]. Recently,
Davies et al have demonstrated that, in addition to plasma
albumin, comorbidity at the start of treatment was as-
sociated with increased solute transport in PD patients
[5, 39]. However, one should remain cautious in interpret-
ing albumin levels in relation to solute transport: rather
2486 Gillerot et al: Genetic and clinical factors inﬂuence the peritoneal membrane
↑ Small solute transport rate across
the peritoneal membrane
Uremic state
IL-6 expression−174G/C IL-6
(Dominant C allele)
(IL-6/sIL-6R signaling → shift in chemokine production)
Growth factors
(VEGF, ...)
Chronic inflammation
Influence on vascular
permeability ↑ CRP release ↓ Albumin production
+
Fig. 5. Hypothetical framework for the effect
of the −174G/C polymorphism of the pro-
moter of IL-6 on the transport of small solutes
across the peritoneal membrane in patients on
peritoneal dialysis. For details see text.
than being a marker of inflammation, lower systemic al-
bumin concentrations may reflect the fluid overload en-
countered in PD patients with high peritoneal perme-
ability. High transporters may also lose albumin in the
dialysate, as suggested by the data in the GC/CC patients
studied here.
CONCLUSION
Our studies, based on genetic and biochemical inves-
tigations, support the hypothesis that underlying mecha-
nisms (regulation of IL-6 gene expression) could regulate
systemic and local inflammation and, in association with
comorbidity and uremia, affect the transport of small so-
lutes across the PM (Fig. 5). These data also suggest that
genetic variants, together with clinical factors, could con-
tribute to the variability in peritoneal transport observed
at baseline. Confirming the strength of the present asso-
ciation, and deciphering the influence of genetic determi-
nants on peritoneal transport will require well-designed,
adequately powered studies, in different populations and
different settings [43], as well as a detailed assessment of
the function of the polymorphisms [44].
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